scPharmaceuticals Inc. (SCPH)
NASDAQ: SCPH · Real-Time Price · USD
4.850
+0.280 (6.13%)
Aug 22, 2025, 4:00 PM - Market closed
scPharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover scPharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14, which forecasts a 188.66% increase in the stock price over the next year. The lowest target is $12 and the highest is $18.
Price Target: $14 (+188.66%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2025.
Analyst Ratings
The average analyst rating for scPharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +147.42% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +271.13% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +271.13% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +271.13% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +271.13% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
75.92M
from 36.33M
Increased by 108.95%
Revenue Next Year
131.97M
from 75.92M
Increased by 73.83%
EPS This Year
-1.07
from -1.91
EPS Next Year
-0.29
from -1.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 84.0M | 157.5M | 262.5M | ||
| Avg | 75.9M | 132.0M | 204.2M | ||
| Low | 69.5M | 110.8M | 159.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.2% | 107.5% | 98.9% | ||
| Avg | 109.0% | 73.8% | 54.7% | ||
| Low | 91.2% | 45.9% | 20.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.95 | 0.26 | 1.58 | ||
| Avg | -1.07 | -0.29 | 0.61 | ||
| Low | -1.15 | -0.69 | 0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.